COVID-19 vaccine candidates and vaccine development platforms available worldwide

The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the...

Full description

Bibliographic Details
Main Authors: ALzaidi, Z. (Author), Aynekin, B. (Author), Beccari, T. (Author), Bertelli, M. (Author), Bilgili, F. (Author), Demirors, B. (Author), Duman, N. (Author), Dundar, M. (Author), Sahin, I.O (Author), Taskin, D. (Author), Turanli, E.T (Author), Yildirim, A. (Author)
Format: Article
Language:English
Published: Xi'an Jiaotong University 2021
Subjects:
Online Access:View Fulltext in Publisher
LEADER 03393nam a2200637Ia 4500
001 10.1016-j.jpha.2021.09.004
008 220427s2021 CNT 000 0 und d
020 |a 20951779 (ISSN) 
245 1 0 |a COVID-19 vaccine candidates and vaccine development platforms available worldwide 
260 0 |b Xi'an Jiaotong University  |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1016/j.jpha.2021.09.004 
520 3 |a The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. © 2021 Xi'an Jiaotong University 
650 0 4 |a antiviral therapy 
650 0 4 |a Article 
650 0 4 |a biotechnology 
650 0 4 |a coronavirus disease 2019 
650 0 4 |a Coronavirus outbreak 
650 0 4 |a COVID-19 vaccine 
650 0 4 |a disease severity 
650 0 4 |a DNA vaccine 
650 0 4 |a drug development 
650 0 4 |a drug efficacy 
650 0 4 |a drug manufacture 
650 0 4 |a human 
650 0 4 |a immune response 
650 0 4 |a live vaccine 
650 0 4 |a morbidity 
650 0 4 |a mortality 
650 0 4 |a nonhuman 
650 0 4 |a reinfection 
650 0 4 |a RNA vaccine 
650 0 4 |a SARS-CoV-2 vaccine 
650 0 4 |a SARS-CoV-2 variants 
650 0 4 |a Severe acute respiratory syndrome coronavirus 2 
650 0 4 |a subunit vaccine 
650 0 4 |a Treatment 
650 0 4 |a vaccination 
650 0 4 |a Vaccine development platform 
650 0 4 |a vector vaccine 
650 0 4 |a virus detection 
650 0 4 |a virus genome 
650 0 4 |a virus like agent 
650 0 4 |a virus transmission 
700 1 |a ALzaidi, Z.  |e author 
700 1 |a Aynekin, B.  |e author 
700 1 |a Beccari, T.  |e author 
700 1 |a Bertelli, M.  |e author 
700 1 |a Bilgili, F.  |e author 
700 1 |a Demirors, B.  |e author 
700 1 |a Duman, N.  |e author 
700 1 |a Dundar, M.  |e author 
700 1 |a Sahin, I.O.  |e author 
700 1 |a Taskin, D.  |e author 
700 1 |a Turanli, E.T.  |e author 
700 1 |a Yildirim, A.  |e author 
773 |t Journal of Pharmaceutical Analysis